Search

Your search keyword '"Doehner, Hartmut"' showing total 712 results

Search Constraints

Start Over You searched for: Author "Doehner, Hartmut" Remove constraint Author: "Doehner, Hartmut"
712 results on '"Doehner, Hartmut"'

Search Results

1. Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin

3. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

5. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

6. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

7. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

8. Model-based optimal AML consolidation treatment

9. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

10. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

12. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications

13. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

14. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

17. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

20. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

22. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

25. Rearrangements involving 11q23.3/KMT2A in adult AML:mutational landscape and prognostic implications - a HARMONY study

26. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial

27. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication

28. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

29. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

30. The ParaHox gene Cdx4 induces acute erythroid leukemia in mice

31. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

32. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

33. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

37. AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

38. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

39. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

43. Human Chromosome 7: DNA Sequence and Biology

45. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

47. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

48. Table S1 from Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence

49. Figure S1 - Figure S8 from Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence

50. Data from Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence

Catalog

Books, media, physical & digital resources